Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Update on Novel Non-Operative Treatment for Osteoarthritis : Current Status and Future Trends

Chen, Tao ; Weng, Weidong ; Liu, Yang LU ; Aspera-Werz, Romina H. ; Nüssler, Andreas K. and Xu, Jianzhong (2021) In Frontiers in Pharmacology 12.
Abstract

Osteoarthritis (OA) is a leading cause of pain and disability which results in a reduced quality of life. Due to the avascular nature of cartilage, damaged cartilage has a finite capacity for healing or regeneration. To date, conservative management, including physical measures and pharmacological therapy are still the principal choices offered for OA patients. Joint arthroplasties or total replacement surgeries are served as the ultimate therapeutic option to rehabilitate the joint function of patients who withstand severe OA. However, these approaches are mainly to relieve the symptoms of OA, instead of decelerating or reversing the progress of cartilage damage. Disease-modifying osteoarthritis drugs (DMOADs) aiming to modify key... (More)

Osteoarthritis (OA) is a leading cause of pain and disability which results in a reduced quality of life. Due to the avascular nature of cartilage, damaged cartilage has a finite capacity for healing or regeneration. To date, conservative management, including physical measures and pharmacological therapy are still the principal choices offered for OA patients. Joint arthroplasties or total replacement surgeries are served as the ultimate therapeutic option to rehabilitate the joint function of patients who withstand severe OA. However, these approaches are mainly to relieve the symptoms of OA, instead of decelerating or reversing the progress of cartilage damage. Disease-modifying osteoarthritis drugs (DMOADs) aiming to modify key structures within the OA joints are in development. Tissue engineering is a promising strategy for repairing cartilage, in which cells, genes, and biomaterials are encompassed. Here, we review the current status of preclinical investigations and clinical translations of tissue engineering in the non-operative treatment of OA. Furthermore, this review provides our perspective on the challenges and future directions of tissue engineering in cartilage regeneration.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cartilage regeneration, gene, non-operative, osteoarthritis, scaffold, tissue engineering
in
Frontiers in Pharmacology
volume
12
article number
755230
publisher
Frontiers Media S. A.
external identifiers
  • scopus:85116244136
  • pmid:34603064
ISSN
1663-9812
DOI
10.3389/fphar.2021.755230
language
English
LU publication?
yes
additional info
Publisher Copyright: © Copyright © 2021 Chen, Weng, Liu, Aspera-Werz, Nüssler and Xu.
id
274a1c2f-cf85-4207-9d3e-925bb5470ebc
date added to LUP
2021-10-26 13:20:39
date last changed
2024-04-20 15:20:34
@article{274a1c2f-cf85-4207-9d3e-925bb5470ebc,
  abstract     = {{<p>Osteoarthritis (OA) is a leading cause of pain and disability which results in a reduced quality of life. Due to the avascular nature of cartilage, damaged cartilage has a finite capacity for healing or regeneration. To date, conservative management, including physical measures and pharmacological therapy are still the principal choices offered for OA patients. Joint arthroplasties or total replacement surgeries are served as the ultimate therapeutic option to rehabilitate the joint function of patients who withstand severe OA. However, these approaches are mainly to relieve the symptoms of OA, instead of decelerating or reversing the progress of cartilage damage. Disease-modifying osteoarthritis drugs (DMOADs) aiming to modify key structures within the OA joints are in development. Tissue engineering is a promising strategy for repairing cartilage, in which cells, genes, and biomaterials are encompassed. Here, we review the current status of preclinical investigations and clinical translations of tissue engineering in the non-operative treatment of OA. Furthermore, this review provides our perspective on the challenges and future directions of tissue engineering in cartilage regeneration.</p>}},
  author       = {{Chen, Tao and Weng, Weidong and Liu, Yang and Aspera-Werz, Romina H. and Nüssler, Andreas K. and Xu, Jianzhong}},
  issn         = {{1663-9812}},
  keywords     = {{cartilage regeneration; gene; non-operative; osteoarthritis; scaffold; tissue engineering}},
  language     = {{eng}},
  month        = {{09}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Pharmacology}},
  title        = {{Update on Novel Non-Operative Treatment for Osteoarthritis : Current Status and Future Trends}},
  url          = {{http://dx.doi.org/10.3389/fphar.2021.755230}},
  doi          = {{10.3389/fphar.2021.755230}},
  volume       = {{12}},
  year         = {{2021}},
}